

Nomi[®]

Zolmitriptan 2.5 mg



Composition

Nomi[®] Tablet: Each film coated tablet contains Zolmitriptan USP 2.5 mg.

Nomi[®] Nasal Spray: Each spray delivers Zolmitriptan USP 2.5 mg.

Pharmacology

Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides through nerve endings in the trigeminal system. The therapeutic activity of **Nomi[®]** for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT_{1B/1D} receptors on intracranial blood vessels and sensory nerves of the trigeminal system which results in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Indication

Nomi[®] is indicated for the acute treatment of migraine with or without aura in adults.

Dosage & administration

The recommended starting dose of **Nomi[®]** is 2.5 mg. Maximum recommended single dose is 5 mg. If the migraine has not resolved by 2 hours after taking **Nomi[®]**, or returns after a transient improvement, a second dose may be administered at least 2 hours after the first dose. The maximum daily dose is 10 mg in any 24-hours period.

Contraindication

Contraindicated in patients with ischemic coronary artery disease, history of stroke, concurrent or recent use of a monoamine oxidase inhibitor and known hypersensitivity to Zolmitriptan.

Warnings and Precautions

There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration. Sensations of tightness, pain, and pressure may occur in the chest, throat, neck, and jaw after treatment with Zolmitriptan.

Adverse reactions

Most common adverse reactions were neck/throat/jaw pain or pressure, dizziness, paresthesia, asthenia, somnolence, warm/cold sensation, nausea, heaviness sensation, and dry mouth.

Use in special population

Pregnancy: Pregnancy Category: C. Zolmitriptan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. **Nursing mother:** It is not known whether Zolmitriptan is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: Not recommended for use in patients under 18 years of age.

Storage

Protect from light and moisture, store below 30°C. Keep the medicine out of the reach of children.

How supplied

Nomi[®] Tablet: Each box contains 12 tablets in blister pack.

Nomi[®] Nasal Spray: Each bottle contains solution adequate for 14 metered doses.

Manufactured by



SQUARE
PHARMACEUTICALS LTD.
BANGLADESH